Hims & Hers' Novo Nordisk Partnership Renewal Masks Escalating Legal Peril

What happened

A Seeking Alpha article rates Hims & Hers a Speculative Buy after renewing its partnership with Novo Nordisk, citing improved access to lucrative GLP-1 therapies and rising gross margins. However, the DeepValue master report reveals that this partnership does not address critical legal and regulatory threats, including a Novo Nordisk patent lawsuit seeking an injunction through 2031 that could halt GLP-1-related activities. Contrary to the article's claim of gross margins rising to nearly 75%, SEC filings show margins actually declined to 74% in FY2025 from 79%, reflecting higher costs from personalized offerings tied to compounded semaglutide. The company faces an SEC investigation, a DOJ referral, and FDA restrictions on mass-marketed compounded drugs, with FY2026 guidance explicitly assuming ongoing access that is now at risk. Thus, while management touts growth, the core investment narrative remains dominated by external enforcement and litigation that could severely disrupt operations.

Implication

The renewed partnership with Novo Nordisk does not resolve the patent infringement suit seeking a permanent injunction, which poses a direct threat to GLP-1 revenue streams essential for meeting FY2026 guidance. FDA enforcement actions and an SEC investigation add compliance costs and potential operational constraints, likely pressuring already deteriorating gross margins. Elevated valuation multiples, with a P/E of 27.8 and EV/EBITDA of 25.2, leave no margin of safety if legal outcomes turn adverse, as net debt stands at $1.04 billion. Near-term catalysts include Q1 2026 results, which must absorb a $65 million headwind from shipping cadence changes, and court developments that could signal injunctive relief. Until these binary risks are de-risked, the stock offers a skewed risk-reward profile biased toward further downside, aligning with the master report's 'POTENTIAL SELL' rating.

Thesis delta

The article suggests a bullish shift due to partnership renewal and margin improvement, but this overlooks the master report's detailed evidence of unresolved legal and regulatory headwinds. The thesis remains unchanged: Hims & Hers is a high-risk equity where external factors, not operational execution, drive near-term value, and the partnership does not alter the probability of adverse outcomes from lawsuits or enforcement actions.